CD274 and neoplasm: Similar to histone methylation‐targeted therapies, HDAC inhibitors can modulate the tumor immune microenvironment by upregulating PD‐L1 expression and reducing Treg populations [122], thereby enhancing antitumor immune responses and supporting their combination with immunotherapies [123, 124].